Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2018

01-03-2018 | AdisInsight Report

Netarsudil Ophthalmic Solution 0.02%: First Global Approval

Author: Sheridan M. Hoy

Published in: Drugs | Issue 3/2018

Login to get access

Abstract

Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa®] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. The recommended dosage is one drop in the affected eye(s) once daily in the evening. Phase III development in the EU and phase II development in Japan are underway for this indication. This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Literature
1.
Abu-Hassan DW, Acott TS, Kelley MJ. The trabecular meshwork: a basic review of form and function. J Ocul Biol. 2014;2(1).
2.
Aptel F, Chiquet C, Romanet JP. Intraocular pressure-lowering combination therapies with prostaglandin analogues. Drugs. 2012;72(10):1355–71.CrossRefPubMed
3.
Donegan RK, Lieberman RL. Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions. J Med Chem. 2016;59(3):788–809.CrossRefPubMed
4.
Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2017:1–12.
5.
Aerie Pharmaceuticals Inc. RHOPRESSA® (netarsudil ophthalmic solution) 0.02%, for topical ophthalmic use: US prescribing information. 2017. https://​www.​fda.​gov/​. Accessed 16 Jan 2018.
6.
Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals announces U.S. FDA approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. 2017. http://​aeriepharma.​com/​. Accessed 16 Jan 2018.
7.
Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals reports positive Rocket 4 six-month topline safety and efficacy results for RhopressaTM (netarsudil ophthalmic solution) 0.02%. 2017. http://​aeriepharma.​com/​. Accessed 16 Jan 2018.
8.
Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals initiates netarsudil ophthalmic solution phase 2 clinical trial designed to meet requirements of regulatory filing in Japan. 2017. http://​aeriepharma.​com/​. Accessed 16 Jan
9.
Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals submits New Drug Application to U.S. Food and Drug Administration for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%. 2016. http://​aeriepharma.​com/​. Accessed 16 Jan 2018.
10.
Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals enters into collaboration agreement with DSM focused on technology to potentially deliver Aerie compounds to treat retinal diseases such as wet AMD. 2017. http://​aeriepharma.​com/​. Accessed 8 Feb 2018.
11.
Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals announces drug delivery asset acquisition to further advance its retinal disease program. 2017. http://​aeriepharma.​com/​. Accessed 8 Feb 2018.
12.
Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016;787:20–31.CrossRefPubMedPubMedCentral
13.
Wang RF, Williamson JE, Kopczynski C, et al. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51–4.CrossRefPubMed
14.
15.
16.
Wu K, Ren R, Li G, et al. Netarsudil increases size of giant vacuoles in Schlemm’s canal of perfused human eyes [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):1074.
17.
Stamer WD, Li G, Agrahari V, et al. Rapid reversal of corticosteroid-induced ocular hypertension by netarsudil [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):3404.
18.
Levy B, Ramirez N, Novack GD, et al. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159(5):980–5.e1.
19.
Sit A. Aqueous humor dynamics of netarsudil ophthalmic solution in humans [abstract no. FP-GLA-080]. In: European Society of Ophthalmology Congress (SOE). 2017.
20.
Weiss M, Levy B, Kopczynski C, et al. Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension. Investig Ophthalmol Vis Sci. 2013;54(15):754.
21.
Peace J, Kopczynski C, Heah T. Ocular hypotensive efficacy of netarsudil ophthalmic solution 0.02% over a 24-hour period: a pilot study [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):2460.
22.
Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302–7.CrossRefPubMed
23.
24.
Khouri AS, Heah T, Kopczynski C, et al. A double-masked, randomized, parallel study of netarsudil ophthalmic solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID in patients with elevated intraocular pressure (ROCKET-4) [abstract]. Invest Ophthalmol Vis Sci. 2017;58(8):2461.
Metadata
Title
Netarsudil Ophthalmic Solution 0.02%: First Global Approval
Author
Sheridan M. Hoy
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0877-7

Other articles of this Issue 3/2018

Drugs 3/2018 Go to the issue

Adis Drug Evaluation

Landiolol: A Review in Tachyarrhythmias

Review Article

Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults

Current Opinion

Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol

Review Article

Efficacy and Safety of Tiotropium in Children and Adolescents

Review Article

Prevention and Treatment of Chronic Postsurgical Pain: A Narrative Review

Adis Drug Evaluation

Belimumab: A Review in Systemic Lupus Erythematosus